Immunology Investor Event

Disruptive technologies driving FiC/BiC medicines - ✓✓ Small Molecules rilzabrutinib eclitasertib/ Antibodies - anti-CD40L - amlitelimab RIPK1 Inhibitor - itepekimab - TNFα Inhibitor - dupilumab - anti-TNFα/IL-23 - IL-17A Blocker sanofi Nanobody® Molecules Synthetic Cytokines - anti-IL-13/TSLP anti-IL-13/OX40L - anti-TNFα/OX40L Non-beta IL-2 Degraders IRAK4 Degrader 5 Respiratory | 4 Dermatology | 4 Gastroenterology | 4 Rheumatology 43 Immunology Investor Event

View entire presentation